N6-methyladenosine-modified CircPSMA7 enhances bladder cancer malignancy through the miR-128–3p/MAPK1 axis

Jiahe Yi(First Affiliated Hospital Zhejiang University), Liping Xie(First Affiliated Hospital Zhejiang University), Dingheng Lu(Union Hospital), Yuqing Wu(Zhejiang University), Zixiang Liu(Zhejiang Cancer Hospital), Xuan Shu(Zhejiang Cancer Hospital), Xiao Wang(Jinan University), Ben Liu(Zhejiang Cancer Hospital), Yijie Tang(Zhejiang University), Yiwei Lin(First Affiliated Hospital Zhejiang University), Jiazhu Sun(First Affiliated Hospital Zhejiang University), Jiangfeng Li(First Affiliated Hospital Zhejiang University), Yufan Ying(Soochow University), Xiangyi Zheng(Tianjin University), Jindan Luo(First Affiliated Hospital Zhejiang University), Xueyou Ma(First Affiliated Hospital Zhejiang University)
Cancer Letters
January 9, 2024
10.1016/j.canlet.2024.216613
Cited by 24

Related Papers

The Lancet Commission on prostate cancer: planning for the surge in cases
|The Lancet|2024|694
YTHDF2 mediates the mRNA degradation of the tumor suppressors to induce AKT phosphorylation in N6-methyladenosine-dependent way in prostate cancer
|Molecular Cancer|2020|383
Transperineal versus transrectal prostate biopsy in the diagnosis of prostate cancer: a systematic review and meta-analysis
|World Journal of Surgical Oncology|2019|276
Downregulation of N6-methyladenosine binding YTHDF2 protein mediated by miR-493-3p suppresses prostate cancer by elevating N6-methyladenosine levels
|Oncotarget|2017|207
Resveratrol induces apoptosis and cell cycle arrest of human T24 bladder cancer cells <i>in vitro</i> and inhibits tumor growth <i>in vivo</i>
|Cancer Science|2009|188